New breast cancer drug to be reimbursed from next month
Abemaciclib approved for treatment of high-risk oestrogen-driven breast cancer Patient advocates and oncologists have welcomed a HSE decision to reimburse a new treatment option for breast cancer that is of high risk of recurrence. Abemaciclib will be …